Skip to content

Clinical trials

Insulin Resistance trials in Denmark

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Insulin Resistance Country / region: Denmark Clear all

149 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20023
20032
20044
20054
20068
20077
200815
20098
20107
20117
20126
20136
20148
20155
20168
20173
20189
20195
20203
20215
20226
20232
20246
20257
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed116
Recruiting12
Unknown status11
Terminated4
Not yet recruiting3
Active, not recruiting2
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Aarhus42
University of Copenhagen35
Aarhus University Hospital8
Rigshospitalet, Denmark8
Odense University Hospital7
University Hospital, Gentofte, Copenhagen7
Hvidovre University Hospital4
Glostrup University Hospital, Copenhagen3
Steno Diabetes Center Copenhagen3
Aalborg University Hospital2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Insulin Resistance149
Diabetes Mellitus, Type 243
Obesity28
Metabolic Syndrome14
Diabetes Mellitus13
Inflammation11
Diabetes Mellitus, Type 110
Glucose Metabolism Disorders7
Non-alcoholic Fatty Liver Disease7
Overweight7

Trials

Showing 51 to 75 of 149. Each trial links to its page on Pharma Observatory.

49 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.